Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.
Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses challenges with androgen deprivation therapy (ADT) in recurrent prostate cancer.
For many years, ADT has been the mainstay of treatment for men with biochemically recurrent or metastatic advanced prostate cancer, says Shore.
However, ADT is associated with significant adverse effects that can negatively impact a patient’s quality of life, Shore explains. Additionally, ADT may increase a patient's risk of cardiovascular events or cognitive impairment.
As such, creating a strategy to target prostate-specific antigen and prostate-specific membrane antigen represents an unmet need, adds Shore.
This unmet need served as the basis for a phase 1/2, open-label, multicenter study that assessed INO-5150, a DNA-based immune therapy, with or without INO-9012, in patients with biochemically recurrent prostate cancer, Shore concludes.